catumaxomab

Drug Overview

Catumaxomab is an advanced Targeted Therapy and Immunotherapy designed to fight certain types of cancer. It is considered a “Smart Drug” because it specifically seeks out cancer cells while simultaneously signaling your body’s immune system to attack them. It is uniquely used to treat a painful complication of advanced cancer called “malignant ascites,” which is a severe buildup of fluid in the belly.

• Generic Name: Catumaxomab
• US Brand Names: None currently. (It was recently approved in Europe in February 2025 under the brand name KORJUNY®; previously known as Removab).
• Drug Class: Trifunctional Bispecific Monoclonal Antibody (T-cell engager).
• Route of Administration: Intraperitoneal (IP) infusion (injected directly into the fluid cavity of the belly).
• FDA Approval Status: Currently, catumaxomab holds an “Orphan Drug” designation from the FDA, meaning it is investigational in the US for rare conditions. However, it received full marketing authorization from the European Medicines Agency (EMA) in 2025.

What Is It and How Does It Work? (Mechanism of Action)

Catumaxomab is an Immunotherapy that works as a highly advanced microscopic bridge. Scientists call it a “trifunctional bispecific antibody” because it has three specific “hands” that grab onto three different targets at the exact same time.

At the molecular level, here is how the three-way connection works:

1. Targeting the Cancer: One “hand” grabs onto a protein called EpCAM (Epithelial Cell Adhesion Molecule). This protein is found in huge amounts on the surface of many tumor cells (like ovarian, gastric, and pancreatic cancer cells).
2. Grabbing the T-Cell: The second “hand” grabs onto CD3, a receptor on your body’s T-cells. T-cells are the “soldiers” of your immune system.
3. Activating the Backup: The “tail” of the drug (the Fc region) alerts other immune cells, like macrophages and natural killer (NK) cells, by binding to their Fc-gamma receptors.

By pulling the cancer cell, the T-cell, and the backup immune cells all together in one tight hug, catumaxomab forces the immune system to recognize and destroy the EpCAM-positive cancer cell. Because it activates so many parts of the immune system, it can also create a long-term “vaccination effect,” teaching your body how to fight off the cancer in the future.

FDA Approved Clinical Indications

Because catumaxomab is currently moving through global regulatory updates (with its major 2025 approval in Europe), its specific statuses are as follows:

Oncological uses:

• Malignant Ascites (EMA Approved): Approved in Europe for the intraperitoneal treatment of malignant ascites (fluid buildup in the belly) in adults with EpCAM-positive cancers who cannot receive standard chemotherapy.
• Non-Muscle Invasive Bladder Cancer (Investigational): Actively being studied in clinical trials for early-stage bladder cancer.
• Gastric and Ovarian Cancers (Investigational): Being researched for treating advanced stomach and ovarian tumors.

Non-oncological uses:

• There are no known uses for this drug outside of cancer treatment.

Dosage and Administration Protocols

Catumaxomab is not given through a standard IV in the arm. Instead, it is given directly into the peritoneal cavity (the space in your belly where the fluid has built up) through a catheter.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Because this drug is put directly into the belly cavity and is broken down into basic amino acids by the immune system (rather than being heavily filtered by the kidneys or liver), standard dose reductions for mild kidney or liver issues are usually not required. However, doctors will monitor liver enzymes very closely.

Clinical Efficacy and Research Results

Recent clinical reviews and trials (2024–2025) leading to the drug’s European approval have highlighted its powerful benefits for patients suffering from advanced cancer fluid buildup.

• Puncture-Free Survival: In major clinical studies (like the IP-REM-AC-01 trial), patients receiving catumaxomab had a statistically significant improvement in “puncture-free survival.” This means the drug successfully stopped the belly fluid from returning, sparing patients from needing painful needles to drain their abdomens every few weeks.
• Quality of Life: Recent 2025 data confirmed that using this Targeted Therapy delayed the deterioration of patients’ overall quality of life and reduced symptom burdens like severe abdominal pain and shortness of breath.
• Bladder Cancer Trials (2024): Ongoing Phase I/II trials for bladder cancer are showing promise that applying the drug directly into the bladder can safely trigger an immune response against tumors that have stopped responding to standard treatments.

Safety Profile and Side Effects

Because catumaxomab forcefully wakes up your immune system, it can cause intense, flu-like reactions as your body fights the cancer.

Warnings and Precautions

While there is no formal FDA “Black Box Warning” yet, drugs in this T-cell engager class carry strict global warnings for Cytokine Release Syndrome (CRS). This is a severe, whole-body immune reaction that can cause dangerously high fevers and drops in blood pressure.

Common Side Effects (>10%)

• Fever and Chills: Very common as the immune system activates.
• Abdominal Pain: Discomfort in the belly where the drug is acting.
• Nausea and Vomiting: Often feeling sick to the stomach during or after treatment.
• Fatigue: Extreme tiredness.

Serious Adverse Events

• Severe Cytokine Release Syndrome (CRS): Trouble breathing, dizziness, or a racing heart.
• Systemic Inflammatory Response Syndrome (SIRS): A widespread inflammation that can stress the major organs.
• Liver Toxicity: Increases in liver enzymes or yellowing of the skin (jaundice).

Management Strategies:

• For CRS and Fever: Your doctor will give you “pre-medications” (like acetaminophen, antihistamines, and sometimes mild steroids) before the infusion to prevent severe fevers and allergic reactions.
• For Pain: Doctors provide pain relief medication during the belly infusion to keep you comfortable.

Connection to Stem Cell and Regenerative Medicine

The target of catumaxomab—the EpCAM protein—is heavily researched in the field of cancer stem cells. In many tumors, a small, stubborn group of cells acts like “cancer stem cells” (tumor-initiating cells). These cells are deeply responsible for cancer spreading (metastasis) and coming back after traditional chemotherapy. Because these cancer stem cells are heavily coated in EpCAM proteins, catumaxomab acts as a direct Targeted Therapy against them. By helping the immune system seek out and destroy these stem-like roots, researchers believe the drug provides a vital tool in preventing tumors from regenerating.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• EpCAM Testing: Your doctor must test a sample of your tumor or belly fluid to confirm that your cancer cells carry the EpCAM marker.
• Liver Function Tests: To ensure your liver is healthy enough to handle the treatment.
• Complete Blood Count (CBC): To check your white blood cell levels before immune activation.

Precautions During Treatment

• Hospital Monitoring: You will usually be monitored in a clinic or hospital for several hours after the infusion to watch for signs of fever or low blood pressure.
• Catheter Care: You must keep the area where the tube enters your belly clean and dry to prevent infection.

“Do’s and Don’ts” List

• DO tell your medical team right away if you feel dizzy, have trouble breathing, or suddenly feel very hot or cold.
• DO drink plenty of fluids and rest on the days you receive your infusions.
• DON’T take any new medications, especially over-the-counter pain relievers or fever reducers, without asking your doctor, as they need to track your true body temperature.
• DON’T ignore severe or suddenly worsening belly pain, as it needs to be checked by your medical team immediately.

Legal Disclaimer

This guide is intended for informational and educational purposes only and does not constitute medical advice. Catumaxomab is an advanced immunotherapy that must only be prescribed and administered by a qualified oncologist in a controlled clinical setting. Regulatory approvals vary globally. Always consult with your healthcare provider to discuss your specific diagnosis, treatment options, and whether a medication or clinical trial is appropriate for you. Never disregard professional medical advice or delay seeking it because of something you have read here.